Plumbing RNAi's Potential: Medicines Co., Alnylam Join Up
The Medicines Co. likes Alnylam Pharmaceuticals Inc.'s RNA interference (RNAi) approach to blocking proprotein convertase subtilisin/kexin type 9 (PCSK9) enough to pay $25 million up front plus as much as $180 million in milestone payments, but how the method might stand up against late-stage antibodies remains to be seen clinically.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter